Citations

Clear

3057 citation(s) found for "Cd, Johnson".

Neonatal Survival After Serial Amnioinfusions for Anhydramnios Due to Fetal Kidney Failure
Baschat, Ahmet A., Johnson, Anthony , Blumenfeld, Yair J., Schenone, Mauro H., Gebb, Juliana , Moldenhauer, Julie S., Zaretsky, Michael V. , Chmait, Ramen H., Gonzalez, Juan M., Rl, Miller, Krispin, Eyal , Shamshirsaz, A H A, Bligard, Katherine H. , Kalan, Amanda, Cortes, Magdalena Sanz, Bendel-Stenzel, Ellen, Menon, Shina , Wong, Cynthia, Kwak, Cecilia, Gallup, J Y, McKenna, Kristin, Marron, L, Tran, Cheryl L. , Behrendt, Nicholas, Galan, Henry L. , Samuels, Joshua, Swinford, Rita, Rosner, Mara, Kush, Michelle L, Nasr, Isam, Vasu, Samhita , Boss, Renee D. , Jelin, Angie C., Thompson, Richard E. , Davis, Jonathan M. , Warren, Daniel , Atkinson, Meredith A. , Gebb, Juliana S , Menon, Shina , Miller, Jena L. , Baschat, Ahmet , Blumenfeld, Yair J. , Schenone, Mauro H , Moldenhauer, Julie S. , Chmait, Ramen H. , Gonzalez, Juan, Cortes, Magdalena Sanz , Moon‐Grady, Anita J. , Bendel‐Stenzel, Ellen , Grimm, Paul, Marron, Leah, Hanna, Christian , Swinford, Rita D., Keiser, Amaris , Rosner, Mara , Nasr, Isam W. , Boss, Renee Denise , Jelin, Angie Child , Hanley, Daniel F.

Mayo Clinic

JAMA | July 1, 2026 | Volume: 336 | Issue: 6 | Pages: 473

10.1001/jama.2026.8568 | PMID 42384373 Get It

Importance Anhydramnios from fetal kidney failure causes lethal pulmonary hypoplasia. Serial amnioinfusions have shown promise in mitigating pulmonary disease from bilateral renal agenesis, but efficacy and safety for other causes of fetal kidney failure are unproven. Objective To assess the efficacy of serial amnioinfusions initiated before 26 weeks’ gestation to mitigate lethal pulmonary hypoplasia in cases of anhydramnios due to fetal kidney failure. Design, Setting, and Participants Prospective, nonrandomized clinical trial conducted at 13 US fetal therapy centers from December 2018 to February 2025. Outcomes for maternal-fetal pairs with anhydramnios before 22 weeks’ gestation due to fetal kidney failure without bilateral renal agenesis are reported; data collection for surviving infants continued until February 13, 2026. Exposure Thirty-two participants underwent serial amnioinfusions with isotonic fluid beginning before 26 weeks’ gestation. Main Outcomes and Measures The primary end point was neonatal survival for 14 days or longer with dialysis access placement. Secondary outcome measures of survival to discharge home and kidney transplant are reported. Results Twenty-nine of 32 participants (91%) had a live birth, with a median (IQR) gestational age at delivery of 34 weeks 1 day (31 weeks 5 days to 34 weeks 6 days). All participants delivered before 37 weeks’ gestation. No unexpected serious maternal adverse events occurred, and the most common maternal complications were preterm prelabor rupture of membranes in 19 participants (56%) and chorioamniotic separation in 10 (29%). The primary outcome occurred in 19 (65.5%) of 29 live-born neonates (95% CI, 45.7%-82.1%). Factors associated with survival to the primary outcome included receiving more amnioinfusions (median [IQR], 14 [9-18] in survivors vs 7 [4-11] in nonsurvivors; P = .01), longer time interval from first amnioinfusion to preterm prelabor rupture of membranes (63.5 [60.5-74.5] days in survivors vs 29.0 [22.0-56.0] days in nonsurvivors; P = .01), gestational age greater than 32 weeks (79% of survivors vs 38% of nonsurvivors; P = .03), and higher birth weight (2029 [1770-2250] g in survivors vs 1635 [1185-1915] g in nonsurvivors; P = .01). Fourteen live-born infants (48%) survived to hospital discharge at a median (IQR) age of 4.7 (3.4-5.7) months. Of the 11 infants surviving to date, 7 (64%) have undergone kidney transplant between ages 2 years to 5 years. Conclusions and Relevance Serial amnioinfusions mitigated lethal pulmonary hypoplasia in neonates with anhydramnios due to fetal kidney failure. Significant neonatal morbidity and mortality independent of early lung function was noted. Factors associated with survival were consistent with the Renal Anhydramnios Fetal Therapy trial’s bilateral renal agenesis cohort, suggesting common mechanistic pathways for mitigating pulmonary hypoplasia. Trial Registration ClinicalTrials.gov Identifier: NCT03101891
Comparison of SARS-CoV-2 Delta Versus Omicron Variant and Its Impact on Immunocompromised Versus Immunocompetent Population
Shah, Sadia , SATASHIA, PARTHKUMAR , Johnson, Patrick W. , Kunze, Katie L. , Khan, A, Sinclair, Jorge, Attieh, Rose Mary , Milian, Ricardo Diaz , Edwards, Michael A. , Carter, Rickey E. , Spiecher, Leigh, Franco, Pablo Moreno , Sanghavi, Devang, Wadei, Hani M. , Carter, Rickey E , Johnson, Patrick W , Moreno Franco, Pablo , Wadei, Hani M , Kunze, Katie L , Diaz Milian, Ricardo , Isha, Shahin , Bhattacharyya, Anirban , Speicher, Leigh L. , Sanghavi, Devang, Shah, Sadia Z. , Edwards, Michael

Mayo Clinic

COVID | June 30, 2026 | Volume: 6 | Issue: 7 | Pages: 111

10.3390/covid6070111 Get It

The Omicron variant of SARS-CoV-2 is associated with milder symptoms and lower hospitalization and mortality rates than Delta variants, although the impact of Omicron on immunocompromised patients, especially solid organ transplant (SOT) recipients, is still unclear. This study compares the hospitalization rate and outcomes between immunocompromised, immunocompetent, and SOT patients during the Delta and Omicron periods. We included adult patients who tested positive for SARS-CoV-2 on PCR or nasopharyngeal antigen test between 26 June 2021 to 8 September 2022, at our institution. A total of 12,401 COVID-19 patients were included, of which 11,055 were immunocompetent, and 1346 were immunocompromised (375 SOT recipients). Throughout the Delta and Omicron outbreaks, immunocompromised patients exhibited higher comorbidities and 30-day hospitalizations, but rates of mechanical ventilation and ICU-level care were like immunocompetent patients. During the Omicron wave, immunocompromised patients had higher unadjusted relative risk estimates (RR = 2.37, 95% CI 1.96–2.87, p < 0.05) than Delta (RR = 1.58, 95% CI 1.24–2.01, p < 0.05), with higher adjusted relative risk for hospitalization in Omicron (RR = 1.50, 95% CI 1.10–2.03, p = 0.01). Analyses show increased hospitalization risk in immunocompromised during the Omicron wave compared to the Delta wave, with no significant difference in hospitalization outcomes. The relative risk of hospitalization for SOT patients was higher in both waves.
PD-L1 deletion or blockade regulate macrophage antigen presentation and checkpoint molecule surface levels
Waddell, Trinity Q Alaka’i , Dong, Haidong , Roh‐Johnson, Minna , Lancaster, Jessica N. , Waddell, Trinity , Dong, Haidong , Lancaster, Jessica N

Mayo Clinic

No container title available | June 29, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.64898/2026.06.23.734016 | PMID 42427499 Get It

Abstract Macrophages in the tumor microenvironment are known to upregulate PD-L1 expression, thereby suppressing T cells through PD-1 ligation. However, the manner in which PD-L1 expression intrinsically impacts macrophages and their immunomodulatory phenotype is less clear. Clarifying this knowledge gap would yield insight into the mechanisms of immunosuppression within the tumor microenvironment. To characterize the macrophage intrinsic role of PD-L1, we used complementary genetic and pharmacological approaches by analyzing primary murine bone marrow-derived macrophages (BMDMs) with complete genetic PD-L1 deletion and wildtype BMDMs treated with anti-PD-L1 blocking antibodies. Macrophages were evaluated across naïve, pro-inflammatory (M1), and tumor conditioned (TCM) polarization states in vitro. Unlike prior reports, neither genetic deletion nor antibody blockade dramatically altered the expression of macrophage polarization markers or in vitro phagocytic capacity. Both conditions consistently reduced surface levels of the M1-associated costimulatory molecule CD80, prompting further analysis of T cell interacting and antigen presenting proteins, in which we revealed disparate effects of genetic deletion and antibody blockade on the surface levels of MHCI, MHCII, PD-1, and PD-L2. These findings suggest that PD-L1 deletion and antibody-mediated blockade contribute to macrophage immune regulatory profiles in distinct manners. This difference supports a model in which PD-L1 functions in macrophages beyond its canonical role as a ligand for PD-1, influencing antigen presentation and checkpoint molecule levels and playing a broader role in immune regulation in the tumor microenvironment.
Clinical and Molecular Effects of TYK2/JAK1 Inhibition in Dermatomyositis
Mangold, Aaron, Vleugels, Ruth Ann , Shahriari, Neda , Castillo, Rochelle , Gehlhausen, Jeffrey, Jiang, Rundong , Haemel, Anna Kaye, Fox, Jennifer Callahan, Bogle, Rachael , Roberts, Bryce T. , Penner, Scott , Li, Xing, Ramirez, Zeni , Tsoi, Alex, Shaw, Katharina, Cascino, Matthew, Johnson, BE, Kahlenberg, J. Michelle, Gudjonsson, Johann E., Paik, Julie J. , Sluzevich, Jason C. , Haemel, Anna K. , Bogle, R, Shaw, Katharina S. , Cascino, Matthew D., Kahlenberg, J. Michelle , Christopher‐Stine, Lisa , Fernandez, Anthony P , Fiorentino, David Franklin , Werth, Victoria P. , Gudjonsson, Johann E

Mayo Clinic

No container title available | June 26, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.64898/2026.06.15.26354270 Get It

Abstract Dermatomyositis is driven by overactivation of type I and II interferons and other proinflammatory cytokines that signal via the JAK-STAT pathway. We conducted a 12-week, open-label study of brepocitinib, an oral TYK2/JAK1 inhibitor, in five adults with severe cutaneous dermatomyositis. Treatment was associated with rapid, clinically meaningful improvement in cutaneous disease activity. Single-cell and spatial transcriptomic profiling of lesional skin showed marked suppression of interferon-responsive pathways and inflammatory cell states by week 4. Together with findings from a Phase 3 randomized trial in DM patients with skin and muscle involvement (VALOR, NCT05437263 ), these data support TYK2/JAK1 inhibition as a promising therapeutic strategy for DM.
Performance of Google NotebookLM for AI-assisted data extraction and consensus statement generation in a heterogenous systematic review on inflammatory bowel disease, obesity, and cardiometabolic comorbidities: A Methodological Report
Samaan, Sami , Devi, Jalpa , VINCENT, Matthew, Coombs, Shannon , Sehgal, Priya , Mohamed, Mouhand , Rai, Victoria , Johnson, Amanda M. , Yarur, Andrés , Barnes, Edward L. , Mohamed, Mouhand F H , Yarur, Andres J , Deepak, Parakkal , Barnes, Edward L , Devi, Jalpa , Sehgal, Priya , Coombs, Shannon , Deepak, Parakkal

Mayo Clinic

No container title available | June 26, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.64898/2026.06.16.26355773 | PMID 42396330 Get It

Abstract Background Large language models (LLMs) offer promise for systematic review data extraction, but performance in complex multidisciplinary domains and utility for clinical statement generation remain insufficiently described. Objectives To evaluate Google NotebookLM for AI-assisted data extraction and RAND/UCLA consensus statement generation in a systematic review of IBD, obesity, and cardiometabolic comorbidities. Methods Studies were organized into domain-specific notebooks; structured prompts generated standardized evidence tables. Two independent reviewers validated outputs against full-text articles using a four-category error classification. Cell-level accuracy and critical accuracy (cells free of major factual errors) were the primary metrics; workflow time was compared against a published conventional extraction benchmark. Concordance between AI-generated and expert-finalized statements was assessed. Results Across 57 articles, 1,710 data cells were extracted; 151 (8.83%) were flagged, yielding 91.17% cell-level accuracy. Major factual errors occurred in only 4 cells (0.23%), for a critical accuracy of 99.77%. Most errors were minor omissions (59.6%) or incomplete extractions (30.5%); domain error rates ranged from 7.08% to 11.33%. The pipeline required 17.7 versus a projected 165.1 person-hours (89.3% reduction). PICO-structured prompting generated 70 candidate statements; 58 of 112 finalized panel statements (51.8%) were AI-derived, and 85.7% were retained in the finalized set. Conclusion Google NotebookLM demonstrates feasibility as a primary extraction and synthesis tool in a multidisciplinary systematic review, with extractive incompleteness as the principal limitation and substantial time savings over conventional approaches. Its novel application to RAND/UCLA consensus statement generation extends AI-assisted evidence synthesis to clinical consensus generation workflow.
Post-Landing Orthostatic Intolerance after Spaceflight: Characterization of Intravenous Fluid Resuscitation in NASA Astronauts
Pleticha, Josef, Varghese, Lydia Johnson Kolaparambil

Mayo Clinic

No container title available | June 26, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.21203/rs.3.rs-10071388/v1 Get It

Abstract Post-landing orthostatic intolerance (OI) is a prevalent consequence of spaceflight and is often empirically treated with intravenous fluids (IVF) post-landing. Yet IVF administration lacks evidence-based guidelines. We conducted a retrospective review of de-identified flight surgeon documentation for 79 astronauts returning from International Space Station missions (2001–2023). Nausea was documented in 39.2% astronauts, vomiting in 27.8%, dizziness or vertigo in 25.3%, and neurovestibular symptoms in 79.7%. IVF were administered to 41.8% astronauts, with marked variability in bolus volume (500–4000 mL). Female sex was associated with higher rates of nausea (p = 0.014) and lightheadedness (p = 0.033); older age with vomiting (p = 0.037). No individual symptom significantly predicted IVF administration. Hemodynamic triggers and post-infusion reassessment were inconsistently documented. Post-landing management varied substantially, with heterogeneous IVF practices and limited protocolized documentation, underscoring the need for standardized, physiology-informed operational guidelines, particularly for future deep-space missions with constrained medical resources.
TMEM119+ microglia MHC class I restricted antigen presentation impacts CD8 T cell memory, effector status, and blood-brain barrier disruption during neurotropic virus infection
Johnson, Aaron , Maynes, Mark , Thelwell, Javonte, Jin, Fang, Hansen, Michael, Jensen, Hadley, Witter, Ryann, Owens, Carley, Hassani, Asma , Lewis, Cody, Forston, Michael D. , Thelwell, Javonte S. , Jensen, Hadley E , Witter, Ryann K, Lewis, Cody L, Hassani, Asma , Seady, Marina, Maynes, Mark, Thelwell, Javonte, Jin, Fang, Witter, Ryann, Lewis, Cody

Mayo Clinic

No container title available | June 24, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.21203/rs.3.rs-10061124/v1 | PMID 42396480 Get It

Abstract The impact of microglia antigen presentation on CNS infiltrating CD8 T cells responses during neurotropic virus infection remains undefined. Using Theiler’s murine encephalomyelitis virus (TMEV) infection of neurons as a model system, we generated H-2K b and H-2D b Tmem119 conditional knockout mice. During TMEV infection, we determined using Tmem119 K b cKO mice that microglia H-2K b contributes to antiviral CD8 T cell proliferation in the brain. Meanwhile, using Tmem119 D b cKO mice we determined that microglia H-2D b increased antiviral CD8 T cell perforin levels and the capacity to induce blood-brain barrier (BBB) disruption. Furthermore, microglial H-2D b was essential for antigen-specific reactivation of CD8 tissue resident memory (TRM) cell recall responses and BBB disruption long after virus had been cleared. These findings demonstrate discrete roles of individual MHC class I genes on microglia in CD8 T cell proliferation, effector functions, memory recall and neuropathology.
ID #759 Outcomes following focal proton therapy for non-metastatic intracranial atypical teratoid/rhabdoid tumor (ATRT)
Indelicato, Daniel, Mailhot-Vega, Raymond, Thompson, Elizabeth , Johnson, Bryan, Morris, Chris, Klawinski, Darren, Ranalli, Nathan, Bradley, J R, Vega, Raymond B. Mailhot , Mailhot Vega, Raymond B , Klawinski, Darren , Ranalli, Nathan J.

Mayo Clinic

Neuro-Oncology Pediatrics | June 24, 2026 | Volume: 2 | Issue: Supplement_1 | Pages: No page available

10.1093/neuped/wuag026.319 Get It

Abstract Background In children with non-metastatic atypical teratoid/rhabdoid tumor (ATRT), proton therapy is increasingly utilized worldwide due to the radiosensitivity of afflicted young patients. General questions persist, however, surrounding dose and volume of radiotherapy. Methods Between 2009-2024, 39 children from a single institution with non-metastatic intracranial ATRT received focal proton therapy at a median age of 2.4 years (range 0.7-19). Twenty-two patients had supratentorial tumors and 27 had gross/near total resection prior to radiation. Most common chemotherapy regimens were ACNS0333 and SJYC07 (n = 10 each) and Dana-Farber (n = 6). Four patients received consolidative high-dose chemotherapy after radiation. The median radiation dose was 50.4 Gy (range, 50.4-54). The cumulative incidence method assessed freedom from selected endpoints.The Fine-Gray method assessed the level of statistical significance between levels of selected prognostic factors. Results With a median followup of 5.2 years (range 0.5-16.2), the 5-yr overall survival, progression-free survival, and local control was 63%, 64%, and 97%, respectively. Thirteen patients developed isolated leptomeningeal failure as first site of recurrence. Only subtotal resection was significantly associated with local recurrence (100% vs 92%, p &lt; 0.05). Patient age, tumor site, extent of resection, radiation dose, and chemotherapy regimen were otherwise not significantly associated with disease control or survival. Four patients experienced symptomatic radiation necrosis, including 1 death: Three of 4 cases received 54 Gy and consolidative intrathecal methotrexate (n = 2) or high dose ACNS0333 intravenous chemotherapy (n = 1, fatal) after radiation. The other patient received 50.4 Gy and necrosis was immediately preceded by ventriculoperitoneal shunt failure. Six patients developed hearing loss requiring aids. One patient developed radiation-induced meningioma a decade following treatment. Conclusion This represents the largest experience reporting 5-year outcomes following focal radiation in children with non-metastatic intracranial ATRT. When applied with a variety of modern chemotherapy regimens in real-world settings, focal proton therapy at a dose of 50.4 Gy may offer the best therapeutic ratio but does not eliminate serious toxicity. If avoidance of craniospinal radiation remains an ongoing priority, further improvement in survival will depend upon systemic therapy.
Real-World Tumor-Infiltrating Lymphocyte Therapy for Metastatic Melanoma: Treatment Delivery, Immune Reconstitution, and Cardiac Monitoring During High-Dose IL-2
Aboelatta, Mohamed A. , Zarka, Jabra , Tchatchua, Nika , Aboelatta, Noureldin A., Johnson, Jeffrey , Jakub, James W. , Desroches, Justin , Wilson-Miller, Justine, Tabiim, Anthony Jagri , Behl, Deepti , Montane, Heather N. , Kottschade, Lisa A. , Dimou, Anastasios , Block, M. , Heath, Elisabeth I. , Doonan, Bently, Seetharam, ­Mahesh , Molina, Julian R. , Charnin, Jonathan E. , Gill, Paula, Lin, Yi, Baral, Binav , Markovic, Svetomir N., Dudek, Arkadiusz Z. , Johnson, Jeffrey E , Tabiim, Anthony , Jakub, James W , Dimou, Anastasios , Montane, Heather N , Dudek, Arkadiusz Z , Zarka, Jabra G , Tchatchua, Nika , Wilson-Miller, Justine L., Doonan, Bently P. , Markovic, Svetomir N.

Mayo Clinic

Current Oncology | June 24, 2026 | Volume: 33 | Issue: 7 | Pages: 379

10.3390/curroncol33070379 | PMID 42505181 Get It

Background/Objectives: Tumor-infiltrating lymphocyte (TIL) therapy is an important option for patients with metastatic melanoma progressing after standard systemic therapy, but real-world data on treatment delivery, toxicity monitoring, and immune recovery remain limited. We evaluated clinical outcomes, treatment tolerance, immune reconstitution, and cardiac biomarker dynamics across three Mayo Clinic sites. Methods: We retrospectively analyzed adults with metastatic melanoma who received lymphodepleting chemotherapy followed by TIL infusion and high-dose interleukin-2 (IL-2) between April 2024 and December 2025. Clinical outcomes, treatment delivery, and adverse events were assessed. Longitudinal immune monitoring included CD4 and CD8 T-cell counts, CD4:CD8 ratio, and immunoglobulin G (IgG) at baseline and follow-up. In a prespecified cardiac sub-cohort, high-sensitivity troponin (hs-Tn) was measured during IL-2 administration to evaluate associations with cardiac events and IL-2 interruption. Results: Thirty-six patients underwent TIL infusion. The objective response rate was 50.0%, including complete responses in 13.9%, and the disease control rate was 72.2%. Median progression-free survival was 3.61 months, and median overall survival was 12.94 months. M1d disease was associated with inferior overall survival on univariable analysis (HR 6.55, 95% CI 2.03–21.17; p = 0.002), with attenuation after multivariable adjustment. Receipt of ≥3 IL-2 doses was associated with longer overall survival on univariable analysis (HR 0.20, 95% CI 0.06–0.64; p = 0.007), but this association also attenuated after adjustment. Longitudinal immune monitoring demonstrated persistent CD4 lymphopenia through 6 months, sustained inversion of the CD4:CD8 ratio, and declining IgG at months 3 and 6. In the cardiac sub-cohort (24 patients; 87 IL-2 doses), post-dose hs-Tn ≥15 ng/L was associated with clinically significant cardiac events (OR 9.6, 95% CI 1.5–60.6; p = 0.016) and IL-2 interruption (OR 3.4, 95% CI 1.1–10.7; p = 0.036). For cardiac events, hs-Tn ≥15 ng/L had 100% sensitivity and 100% negative predictive value. Conclusions: In routine practice, TIL therapy was feasible and active in metastatic melanoma. M1d disease identified a subgroup with poor survival, peri-dose hs-Tn showed promise as a tool to support safer IL-2 delivery, and prolonged CD4 suppression with IgG decline suggests that recovery after TIL therapy extends beyond initial hematologic reconstitution. These findings support prospective validation of biomarker-guided IL-2 monitoring and extended post-treatment immune surveillance.